Acycloguanosyl 5′-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice

Gastroenterology

Volumn 140, Issue 2, 2011, Pages 709-720.e9

  Polvani, Simone ^a,b   Calamante, Massimo ^c   Foresta, Valeria ^b   Ceni, Elisabetta ^b   Mordini, Alessandro ^b   Quattrone, Alessandro ^b   D'Amico, Massimo ^b   Luchinat, Claudio ^b   Bertini, Ivano ^b   Galli, Andrea ^b  

^a FiorGen   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c ProtEra Srl   (Italy)

Author keywords

hTERT; Human Telomerase Reverse Transcriptase; Suicide Gene Therapy; Telomere

Indexed keywords

ACICLOVIR; ACYCLOGUANOSYL 5' THYMIDYLTRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; PRODRUG; TELOMERASE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ACYCLOGUANOSYL 5'-THYMIDYLTRIPHOSPHATE; DRUG DERIVATIVE; GUANOSINE; PYRIMIDINE NUCLEOTIDE; THYMIDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ANIMAL; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GUANOSINE; HUMANS; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PRODRUGS; TELOMERASE; THYMIDINE; THYMINE NUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251564777     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.10.050     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
2. H.A. Burris III, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
3. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
4. A.H. Ko, E. Dito, and B. Schillinger A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 26 2008 463 471
5. F. Kullmann, S. Hollerbach, and M.M. Dollinger Cetuximab plus gemcitabine/oxaliplatin (gemoxcet) in first-line metastatic pancreatic cancer: a multicentre phase II study Br J Cancer 100 2009 1032 1036
6. E. Van Cutsem, H. van de Velde, and P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
7. C. Hebrard, C. Dumontet, and L.P. Jordheim Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues Cancer Gene Ther 16 2009 541 550
8. C. Altaner Prodrug cancer gene therapy Cancer Lett 270 2008 191 201
9. S.S. Ghosh, P. Gopinath, and A. Ramesh Adenoviral vectors: a promising tool for gene therapy Appl Biochem Biotechnol 133 2006 9 29
10. J.M. Kaplan Adenovirus-based cancer gene therapy Curr Gene Ther 5 2005 595 605
11. D. Jacob, J. Davis, and H. Zhu Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the trail gene from the human telomerase reverse transcriptase promoter Clin Cancer Res 10 2004 3535 3541
12. D. Jacob, J.J. Davis, and L. Zhang Suppression of pancreatic tumor growth in the liver by systemic administration of the trail gene driven by the htert promoter Cancer Gene Ther 12 2005 109 115
13. R.G. Painter, N.A.J. Lanson, and Z. Jin Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis Cancer Sci 96 2005 607 613
14. C. Bonini, A. Bondanza, and S.K. Perna The suicide gene therapy challenge: how to improve a successful gene therapy approach Mol Ther 15 2007 1248 1252
15. L.A. Alexandrova, A.Y. Skoblov, and M.V. Jasko 2′-Deoxynucleoside 5′-triphosphates modified at α-, β- and γ-phosphates as substrates for DNA polymerases Nucleic Acids Res 26 1998 778 786
16. A.A. Arzumanov, D.G. Semizarov, and L.S. Victorova Gamma-phosphate- substituted 2′-deoxynucleoside 5′-triphosphates as substrates for DNA polymerases J Biol Chem 271 1996 24389 24394
17. C.M. Counter, W.C. Hahn, and W. Wei Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization Proc Natl Acad Sci U S A 95 1998 14723 14728
18. M. Meyerson Telomerase enzyme activation and human cell immortalization Toxicol Lett 102103 1998 41 45
19. S.A. Stewart, and R.A. Weinberg Telomeres: cancer to human aging Annu Rev Cell Dev Biol 22 2006 531 557
20. L.C. Fry, K. Mnkemller, and P. Malfertheiner Molecular markers of pancreatic cancer: development and clinical relevance Langenbecks Arch Surg 393 2008 883 890
21. W.C. Hahn, S.A. Stewart, and M.W. Brooks Inhibition of telomerase limits the growth of human cancer cells Nat Med 5 1999 1164 1170
22. J.C. Garber Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the care and use of laboratory animals National Research Council, editors 2002 National Academy Press
23. M. Yoshikawa, T. Kato, and T. Takenishi A novel method for phosphorylation of nucleosides to 5′-nucleotides Tetrahedron Lett 50 1967 5065 5068
24. D.E. Hoard, and D.G. Ott Conversion of mono- and oligodeoxyribonucleotides to 5-triphosphates J Am Chem Soc 87 1965 1785 1788
25. S.S. Chan, and S. Chang Defending the end zone: studying the players involved in protecting chromosome ends FEBS Lett 584 2010 3773 3778
26. J.I. Johnson, S. Decker, and D. Zaharevitz Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer 84 2001 1424 1431
27. T. Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside J Gastroenterol 43 2008 905 911
28. M. Mimeault, R.E. Brand, and A.A. Sasson Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies Pancreas 31 2005 301 316
29. M.W. Saif, L. Karapanagiotou, and K. Syrigos Genetic alterations in pancreatic cancer World J. Gastroenterol 13 2007 4423 4430
30. L.Z. Rubsam, B.L. Davidson, and D.S. Shewach Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-d-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing Cancer Res 58 1998 3873 3882
31. M.M. Shaw, W.K. Grr, and P.A. Watts Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells Antivir Chem Chemother 12 2001 175 186
32. X.W. Tong, D.G. Engehausen, and R.H. Kaufman Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy Anticancer Res 18 1998 713 718
33. T.M. Bryan, A. Englezou, and L. Dalla-Pozza Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines Nat Med 3 1997 1271 1274
34. N. Skrobot Vidacek, A. Cukusi, and M. Ferenac Kis Telomere dynamics and genome stability in the human pancreatic tumor cell line miapaca-2 Cytogenet Genome Res 119 2007 60 67
35. J.A. Kyte Cancer vaccination with telomerase peptide gv1001 Expert Opin Investig Drugs 18 2009 687 694
36. T.O. Kirby, A. Rivera, and D. Rein A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity Clin Cancer Res 10 2004 8697 8703
37. T. Wirth, F. Kuhnel, and S. Kubicka Telomerase-dependent gene therapy Curr Mol Med 5 2005 243 251
38. H.J. Steer, R.A. Lake, and A.K. Nowak Harnessing the immune response to treat cancer Oncogene 29 2010 6301 6313